01—Abstract
Summary
Summary of the 8-K filed November 3, 2026. Cited figures are marked; the original filing is the authoritative source.
Pfizer Inc. (PFE) announced on November 3, 2026, the permanent appointment of Cecile Guegan as Chief Financial Officer (CFO) and Executive Vice President, effective November 1, 2026.
Ms. Guegan has been serving as Interim CFO since August 16, 2026, and possesses over 25 years of global finance leadership experience within the pharmaceutical industry, including extensive tenure at Pfizer and prior roles stemming from the Wyeth acquisition. This appointment solidifies Pfizer's financial leadership with an executive deeply familiar with the company's operations and strategic priorities.
Ms. Guegan's compensation package includes an annual base salary of $1,300,000a and an equal target annual cash incentive opportunity. Her responsibilities will encompass all corporate finance functions, aiming to drive disciplined capital allocation and targeted investments for future revenue growth, as highlighted in her statement about positioning Pfizer for durable long-term growth and shareholder value creation.
02—Key points
Key Highlights
- Cecile Guegan officially appointed Chief Financial Officer (CFO) and Executive Vice President, effective November 1, 2026.
- Ms. Guegan has extensive experience, with over 25 years in pharmaceutical finance, including a prior role in the Wyeth acquisition and various finance leadership positions at Pfizer.
- She has been serving as Interim CFO since August 16, 2026, indicating a seamless transition and proven performance in the role.
- Her compensation includes an annual base salary of $1,300,000 and an annual target cash incentive of $1,300,000 (100% of base salary).
- Ms. Guegan's strategic focus is on disciplined capital allocation and targeted investments to drive future revenue growth and shareholder value.
- She will oversee all corporate finance functions, including treasury, investor relations, tax, and financial planning & analysis.
03—Questions
Frequently Asked Questions
What is the significance of Cecile Guegan's appointment as CFO?
Cecile Guegan's permanent appointment as CFO signifies Pfizer's confidence in her leadership and extensive financial expertise within the pharmaceutical sector. Her prior experience as Interim CFO since August 2026 suggests a smooth transition and continuity in financial strategy, crucial for investor confidence and operational stability.
What is Ms. Guegan's background and experience relevant to her new role?
Ms. Guegan brings over 25 years of global finance leadership experience in the pharmaceutical industry. Her tenure at Pfizer includes significant roles across various divisions like Oncology, R&D, and the Global Biopharmaceuticals Group, in addition to her leadership positions stemming from the Wyeth acquisition. She also served as Senior Vice President of Finance for the Global Biopharmaceuticals business before her interim CFO role.
What are the key compensation details for Ms. Guegan?
Ms. Guegan's compensation includes an annual base salary of $1,300,000. Additionally, she has an annual target cash incentive opportunity of $1,300,000, which is 100% of her annual base salary, contingent on performance metrics.
What is Ms. Guegan's stated focus as CFO?
Ms. Guegan's primary focus is on executing a disciplined approach to capital allocation and making targeted investments to drive future revenue growth. She aims to position Pfizer for durable long-term growth and shareholder value creation.
04—Continue